Millie
your market intelligence analyst
Search Results
Edit Save
149 results
Ovarian Cancer News Today 02/17/2020 08:00
Analysis of cells in the fallopian tube, from which most ovarian cancers develop, can help classify ovarian cancer subtypes, with potential implications for cancer prognoses and treatment strategies, a new study shows. The study, “The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells,” was published in Cancer […]. .
Ovarian Cancer News Today 02/12/2020 08:00
Immune responses in women with advanced ovarian cancer being treated with DPX-Survivac in clinical trials continue to support the immunotherapy’s potential, alone or in combination, to be effective in this patient population. DPX-Survivac, developed by IMV, is being seen to elicit significant anti-tumor responses in these ovarian cancer patients. It works by inducing strong and sustained survivin-specific immune […]. .
Ovarian Cancer News Today 02/07/2020 08:00
Researchers at Northwestern University have identified and mapped the location of structural proteins within pig’s ovaries, which closely resemble human ovaries. This will help the development of an ovary-specific bio-ink that can be used to three-dimensionally (3-D) print artificial, implantable human ovaries that will allow infertile women to bear children. “This is a huge step […]. .
Ovarian Cancer News Today 01/31/2020 08:00
Nami Therapeutics is developing a new form of targeted therapy that aims to be more effective and less toxic than other treatments for advanced forms of ovarian cancer. The new therapy uses small particles (nanoparticles) that are specifically designed to deliver a toxic radioactive compound called holmium-166 (Ho-166) to ovarian cancer cells, while leaving healthy […]. .
Ovarian Cancer News Today 01/28/2020 11:40
Syros Pharmaceuticals announced the dosing of the first patient in its Phase 1 trial of SY-5609, an investigational oral medication for ovarian cancer and other types of solid tumors. The Phase 1 trial (NCT04247126) is a multi-center, open-label, dose-escalation study that plans to enroll approximately 60 people with advanced forms of ovarian, breast, colorectal, or […]. .
Ovarian Cancer News Today 01/27/2020 12:20
Cycle for Survival is kicking off the first of its high-energy indoor cycling events with the goal of surpassing the $42 million raised last year to help defeat rare malignancies such as ovarian cancer. Events this year began Jan. 25 and will continue through early March in 19 cities nationwide. Instructors from Equinox — Cycle […]. .
Ovarian Cancer News Today 01/24/2020 08:00
Mereo BioPharma has licensed its experimental therapy navicixizumab (OMP-305B83) — designed to treat advanced, heavily pretreated ovarian cancer — to Oncologie for worldwide development and commercialization. Under the terms of the agreement, Mereo will get an upfront payment of $4 million. That will be followed by a $2 million outlay contingent upon a milestone known as CMC, […]. .
Ovarian Cancer News Today 01/17/2020 13:43
After decades of conflicting evidence about the possible link between talc powder in the genital area and ovarian cancer, the largest study conducted to date has found no strong connection between the two. While called “overall reassuring” in an editorial, researchers caution that the study was “underpowered” to identify a small increase in risk — […]. .
Ovarian Cancer News Today 01/16/2020 13:15
The first participant has been dosed in a Phase 1 clinical trial evaluating Tmunity Therapeutics‘ CAR T-cell therapy, CART-TnMUC1, in people with certain solid tumors, including ovarian cancer, that are positive for the TnMUC1 protein. The open-label trial (NCT04025216), which is still recruiting, is expected to enroll about 80 people with previously treated cancers that […]. .
Ovarian Cancer News Today 01/14/2020 14:28
The U.S. Food and Drug Administration (FDA) has agreed to review AstraZeneca and Merck‘s request to extend the indication of oral Lynparza (olaparib) as a first-line maintenance therapy in combination with bevacizumab for treating women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA mutation status.
Ovarian Cancer News Today 01/08/2020 14:36
A second surgery followed by chemotherapy is no better than chemotherapy alone at extending the lives of women with platinum-sensitive ovarian cancer who experienced disease recurrence after a first surgery. Instead, it might shorten their lives, findings from a Phase 3 clinical trial show. Results from the first randomized trial testing the approach challenge the routine […]. .
Ovarian Cancer News Today 12/20/2019 11:03
Aravive is recruiting participants for a Phase 1/2 clinical trial assessing a combination of its experimental treatment AVB-500 plus the immune checkpoint inhibitor Imfinzi (durvalumab) in women with platinum-resistant epithelial ovarian cancer. The trial (NCT04019288) is ongoing at the MD Anderson Cancer Center, in Texas, and is expected to include 36 participants with high grade […]. .
Ovarian Cancer News Today 12/17/2019 10:12
ImmunoGen is planning to open an open-label, pivotal clinical trial of mirvetuximab soravtansine in platinum-resistant ovarian cancer patients with high levels of the folate receptor alpha (FRα) protein early next year, the company announced. Results could lead to the treatment’s accelerated, and conditional, approval by the U.S. Food and Drug Administration (FDA), the company announced in a […]. .

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities

Sources

Strategic Scenarios

Trends